Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026)
Fortrea Holdings (FTRE) posted Liabilities and Shareholders Equity of $2.7 billion for Q1 2026, down 1.19% on a QoQ basis from $2.7 billion in Q4 2025, and down 14.02% year-over-year from $3.1 billion in Q1 2025.
Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Fortrea Holdings' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $2.7 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 14.02% year-over-year to $2.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 billion (down 21.2% YoY) and the FY2025 annual result came in at $2.7 billion, down 24.13% from the prior year.
- Liabilities and Shareholders Equity was $2.7 billion for Q1 2026 at Fortrea Holdings, down from $2.7 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $4.4 billion in Q2 2023 and bottomed at $2.7 billion in Q1 2026.
- A 5-year average of $3.6 billion and a median of $3.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity climbed 1.04% — and 2025, when it slipped 26.39%.
- Fortrea Holdings' Liabilities and Shareholders Equity stood at $4.3 billion in 2022, then increased by 1.04% to $4.3 billion in 2023, then retreated by 17.39% to $3.6 billion in 2024, then decreased by 24.13% to $2.7 billion in 2025, then declined by 1.19% to $2.7 billion in 2026.
- Business Quant data shows FTRE's Liabilities and Shareholders Equity at $2.7 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 2.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.74 Bn |
| Jun 30, 2025 | 2.84 Bn |
| Mar 31, 2025 | 3.12 Bn |
| Dec 31, 2024 | 3.58 Bn |
| Sep 30, 2024 | 3.66 Bn |
| Jun 30, 2024 | 3.57 Bn |
| Mar 31, 2024 | 4.24 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Sep 30, 2023 | 4.32 Bn |
| Jun 30, 2023 | 4.36 Bn |
| Dec 31, 2022 | 4.29 Bn |